Escitalopram Neuroimaging Supplement
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 3/30/2013 |
| Start Date: | December 2008 |
| End Date: | February 2013 |
| Contact: | Natalei L Matheny, BA |
| Email: | nmatheny@partners.org |
| Phone: | 617-724-4354 |
Cerebral Metabolic Correlates of Treatment Response to Escitalopram in Body Dysmorphic Disorder
The purpose of this study is to find out more about the brain's response to selective
serotonin reuptake inhibitor (SSRIs) treatment in people with body dysmorphic disorder
(BDD). The investigators will use positron emission tomography (PET) and Magnetic Resonance
Imaging (MRI) scans to look at brain activity in people with BDD before and after treatment
with an SSRI. The investigators hope that what is learned will allow prediction of whether
someone will improve with SSRI treatment.
The investigators have chosen to focus on five regions of interest, namely ACC, OFC,
caudate, amygdala and hippocampus. These are brain regions that have been previously
associated with obsessive-compulsive, affective, and psychotic phenomena. The investigators
will test for correlations between pre-treatment FDG brain images and subsequent SSRI
treatment outcome to identify potential predictors of treatment response. Finally, the
investigators will compare pre-treatment and post-treatment PET FDG studies as well as MRI
studies in BDD subjects to examine changes in these brain regions following treatment. The
goals of the proposed research are to use FDG-PET and MRI to identify predictors of
treatment response to SSRIs in BDD and to determine changes in rCMRglu in BDD subjects
following treatment with SSRIs.
Inclusion Criteria:
- male or female.
- from 18-64 years of age.
- right-handed, by virtue of assessment with the Edinburgh Handedness Inventory
- capacity to render informed consent.
- already enrolled in clinical study NCT00149799.
- must be an outpatient with a primary (the condition that is most central to the
patient's current distress) psychiatric diagnosis of BDD, as defined by DSM-IV
criteria and by a BDD Yale-Brown Obsessive-Compulsive Scale Score greater than or
equal to 24.
Exclusion Criteria:
- with serious medical illness or instability for which hospitalization may be likely
within four months of entry into the study, or current renal insufficiency or
diabetes.
- any pregnant or lactating women or those of childbearing potential not using
medically accepted forms of contraception will be excluded. Pregnancy status will be
determined by administration of a blood beta-HCG test prior to each PET scan.
- with recent or anticipated radiation exposure, which, combined with the exposure in
the present study, will exceed allowable annual limits for the subject
- with a history of hypersensitivity to any component of FDG
- with specific comorbid psychiatric diagnoses (alcohol abuse or dependence within the
past 3 months, bipolar disorder, psychosis, organic mental disorder, development
disorder, borderline personality disorder, body image concerns accounted for
primarily by an eating disorder or weight concerns). If subjects have another
comorbid diagnosis, the BDD must be the primary concern.
- MRI- incompatibilities (for example, metal implants, pacemakers)
We found this trial at
1
site
Click here to add this to my saved trials
